A synthetic piece of Thymosin Beta-4 that promotes healing body-wide ā regardless of where you inject it. Here's what the research actually says.
Research context only. TB-500 is not FDA-approved. All content is educational based on published research.
TB-500 is a synthetic version of a peptide called Thymosin Beta-4 (TĪ²4) ā specifically a fragment of it (amino acids 17-23) that retains most of its biological activity. Thymosin Beta-4 is a naturally occurring protein found in virtually every cell in the human body. It was first isolated from the thymus gland, but it's not a thymus-exclusive compound ā it's ubiquitous in tissue and plays a central role in how cells repair themselves.
The name "TB-500" comes from a commercial preparation of the peptide used in veterinary research ā primarily to speed recovery in racehorses. It's since become one of the most widely researched peptides for systemic tissue repair in human research contexts.
The short version: TB-500 is a piece of a protein your body already makes. It promotes healing, reduces inflammation, and supports cell migration ā the biological process of moving repair cells to where they're needed. Think of it as turning up the volume on your body's existing repair machinery.
What makes TB-500 distinct from most healing peptides is its systemic action. BPC-157, for comparison, works best when administered near the injury site. TB-500 works body-wide regardless of injection location ā it circulates and finds damaged tissue.
TB-500's primary mechanism is binding to actin ā a structural protein that forms the skeleton of cells. By sequestering G-actin (the building block form), TB-500 facilitates cell migration. Cells need to reorganize their actin skeleton to move, and TB-500 makes that process more efficient.
Repair cells ā including macrophages, keratinocytes, and endothelial cells ā need to migrate to damaged tissue. TB-500 dramatically upregulates this migration, getting the right cells to the right place faster than normal healing would allow.
TB-500 increases vascular endothelial growth factor (VEGF), which drives angiogenesis ā the formation of new blood vessels. New vasculature delivers oxygen and nutrients to healing tissue, accelerating recovery.
TB-500 downregulates inflammatory cytokines including NF-ĪŗB and TNF-Ī±. This reduces the chronic inflammation that slows tissue healing ā particularly relevant for tendon, ligament, and joint injuries that tend to stay inflamed.
Why systemic matters: Most peptides need to be injected close to the target tissue. TB-500's mechanism works at a cellular level throughout the body ā it doesn't need to be at the injury site to find it. This makes it particularly practical for injuries in hard-to-reach anatomical locations.
The bulk of TB-500 research comes from animal models ā rodent and equine studies showing accelerated healing of tendons, muscles, ligaments, and skin wounds. Human clinical trial data is limited, but the mechanistic evidence and widespread veterinary use provide a meaningful evidence base.
Key research findings include: accelerated tendon healing in rodent models, improved cardiac repair after myocardial infarction (a notable area of ongoing research), corneal wound healing, and hair follicle regeneration. The cardiac repair data is particularly interesting ā TĪ²4 appears to promote stem cell migration and cardiomyocyte survival after ischemic injury.
Evidence caveat: Most TB-500 research is preclinical. The human data is largely anecdotal from athletic and research communities. The mechanism is well-established; the clinical magnitude of effect in humans is less precisely characterized than compounds with Phase 2/3 trials.
TB-500 + BPC-157 stack: The two peptides are frequently researched together. BPC-157 provides localized healing via angiogenesis and growth factor upregulation; TB-500 provides systemic repair via cell migration and anti-inflammatory pathways. Mechanistically complementary ā which is why S1 Research sells them as a bundle.
TB-500 has a relatively clean reported side effect profile in research and veterinary use. The most commonly reported issues:
The longer-term concern researchers flag is TB-500's role in angiogenesis. VEGF upregulation is what makes it effective for healing ā but increased blood vessel formation could theoretically support existing tumor growth. This is not unique to TB-500 (it applies to any angiogenic compound) and hasn't been demonstrated as a clinical problem at research doses, but it's the standard caution for individuals with a history of cancer.
TB-500 is a peptide ā a small protein fragment. It has no androgenic activity, no effect on testosterone or estrogen, and no mechanism shared with anabolic steroids. It won't appear on steroid panels.
TB-500's systemic mechanism means injection location doesn't significantly affect where it works. It distributes throughout the body and is drawn to areas of tissue damage. Standard SubQ injection anywhere is sufficient.
Different peptide, different mechanism, different primary use cases. BPC-157 works locally through growth factor and nitric oxide pathways. TB-500 works systemically through actin/cell migration. They're complementary, not interchangeable.
COA-verified vendor pricing with promo codes, reconstitution guide, and dosing protocol.
View Pricing ā Dosage Calculator